TSTeodor Serban

Teodor Serban

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teodor Serban has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic value of isolated PR interval prolongation after transcatheter aortic valve implantation

    by Teodor Serban, Marc Salis, Arianna Bettelini, Céline Moser, Andrea Papa, Sven Knecht, Thomas Nestelberger, Christoph Kaiser, Gregor Leibundgut, Beat Schaer, et al.

  • REPLY

    by Teodor Serban, Michael Kühne, Patrick Badertscher

  • Open Access

    Prevalence of arrhythmia-induced cardiomyopathy: A systematic review and meta-analysis

    by Teodor Serban, Tatjana Müller, Sven Knecht, Qurrat-Ul-Ain Abid, Henry Huang, Behnam Subin, Fabian Jordan, Philipp Krisai, Felix Mahfoud, Michael Kühne, et al.


  • Open Access

    Risk Stratification in Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

    by Patrick Badertscher, Teodor Serban, Gregoire Massoullie, Romain Eschalier, Lena Rivard, Delphine Portelance, Ron Waksman, Valerie Pavlicek, Patrizio Pascale, Mattia Pagnoni, et al.


  • Open Access

    Inconclusive Single-Lead ECGs From Smart-Devices

    by Corinne Isenegger, Diego Mannhart, Simon Weidlich, Jonas Brügger, Teodor Serban, Fabian Jordan, Philipp Krisai, Sven Knecht, Nicolas Schaerli, Behnam Subin, et al.


  • Open Access

    Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve Replacement

    by Patrick Badertscher, Stefan Stortecky, Teodor Serban, Sven Knecht, Dik Heg, David Tueller, Raban Jeger, Oliver Reuthebuch, Olivier Muller, Stefan Toggweiler, et al.


  • Different Approaches to Atrial Fibrillation Ablation in Heart Failure Patients

    by Marco Bergonti, Philipp Krisai, Ciro Ascione, Thomas Pambrun, Domenico G. Della Rocca, Paolo Compagnucci, Tardu Özkartal, Lorenzo Marcon, Teba Gonzalez Ferrero, Luigi Pannone, et al.


  • Open Access

    Definition and management of arrhythmia-induced cardiomyopathy: findings from the EHRA SIC survey

    by T Serban, P Badertscher, J Du Fay De Lavallaz, R Providencia, F Migliore, G Mugnai, D Penela, L Perrotta, M Kuehne, C Sticherling, et al.

    Background: Arrhythmia-induced Cardiomyopathy (AiCM) represents a subtype of heart failure (HF) in the context of a sustained arrhythmia. However, clear definitions and management recommendations for AiCM are lacking. Purpose: The European Heart Rhythm Association Scientific Initiatives Committee (EHRA SIC) conducted a survey to determine the current definitions and management of patients with AiCM among European and non-European electrophysiologists. Methods: A 25-item online questionnaire was developed and distributed among EP research network centres between September 4th and October 5th 2022. Results: Out of the 206 respondents, 16% were females and the most (33%) were between 40-49 years old. Most of the respondents were EP-Specialists (81%) working at a University Hospital (47%). While most participants (67%) agreed that AiCM should be defined as a left ventricular ejection fraction (LVEF) impairment after new onset of an arrhythmia and/or LVEF recovery after treatment of the culprit arrhythmia, only 35% identified a specific LVEF drop/improvement to diagnose AiCM, the majority (50%) agreeing with a 10% change in LVEF (Figure) but with the rest of the experts choosing a wide range of values (from 5 to 20% LVEF drop). Most respondents used all available therapies in AiCM patients: catheter ablation was chosen by 93%, electrical cardioversion by 83%, antiarrhythmic drugs by 76% and adjuvant HF treatment were used by 76%. 83% of respondents indicated that adjuvant HF treatment should be started at first diagnosis of HF prior to antiarrhythmic treatment and 84% agreed that the therapy should be stopped within six months after LVEF normalization. Responses for the optimal time point for the first reassessment of LVEF during FU varied markedly (1 day to over 6 months after antiarrhythmic treatment). Conclusion: This EHRA Survey reveals varying practices in defining and managing AiCM among European and non-European physicians. There is an unmet need for a consensus in the definition and management of AiCM patients to improve patient care.Figure

  • Open Access

    Biomarkers to predict improvement of left ventricular ejection fraction after atrial fibrillation ablation

    by T Serban, E Hennings, I Strebel, S Knecht, J Du Fay De Lavallaz, P Krisai, R Arnet, G Voellmin, S Osswald, C Sticherling, et al.

    Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist. Catheter ablation (CA) of AF is increasingly used in patients with AF and HF. However, prediction of improvement of HF after CA is challenging. Aim: We aimed to evaluate the value of biomarkers, alone and in conjunction with a clinical tool (Antwerp score) to predict left ventricular ejection fraction (LVEF) recovery after CA in patients with AF and HF. Methods: Patients undergoing CA for AF with depressed LVEF ( 40% at follow-up in case of HFrEF) and "non-responders" (no LVEF recovery after CA). Models were constructed by comparing the plasma levels of the various biomarkers in responders and non-responders and by adjusting for age, sex, and Antwerp score and subsequent biomarkers were then combined according based on likelihood-ratios. The predictive power of the biomarkers alone and combined in outcome prediction, as well as improvement of the Antwerp score was then evaluated. Results: Out of 1665 patients undergoing CA of AF, we included 208 patients with depressed LVEF (median age 63 years, 19% female, median LAVI 42 ml/m2, median LVEF 43%). The median follow-up time was 30 months [IQR 20-34] and the median time to LVEF recovery was 8 months [IQR 3-22]. Of these, 161 (77%) were responders and 47 (23%) were non-responders. Out of 13 biomarkers, four biomarkers (ANG2, GDF15, FGF23 and MyBPC3) were significantly different between responders and non-responders (p ≤0.001). A biomarker panel using these four biomarkers could predict LVEF recovery after CA for AF with an AUC of 0.72 (95%CI 0.64-0.81) overall, 0.69 (95%CI 0.59-0.78) in HFmrEF and 0.88 (95%CI 0.77-0.98) in HFrEF (Figure, A). Only ANG2 and GDF15 remained significantly associated with LVEF recovery after adjustment for age, sex, and the Antwerp score. The AUC of the Antwerp score for prediction of LVEF recovery improved from 0.75 (95% CI 0.67-0.83, Figure, B) to 0.78 (95% CI 0.70-0.86, Figure, C) in the overall population, from 0.71 (95% CI 0.61-0.81) to 0.74 (95% CI 0.64-0.84) in case of HFmrEF and from 0.87 (95% CI 0.78-0.97) to 0.92 (95% CI 0.85-0.99) in case of HFrEF when ANG2 and GDF15 were included in the model. Conclusion: A biomarker panel using ANG2, GDF15, FGF23 and MyBPC3 performs similarly for prediction of LVEF recovery after CA in AF compared to the Antwerp score. The biomarkers ANG2 and GDF15 slightly improve the predictive value of the Antwerp score.Figure

  • Open Access

    Definition and management of arrhythmia-induced cardiomyopathy: findings from the European Heart Rhythm Association survey

    by Teodor Serban, Patrick Badertscher, Jeanne du Fay de Lavallaz, Rui Providencia, Federico Migliore, Giacomo Mugnai, Diego Penela, Laura Perrotta, Michael Kühne, Christian Sticherling, et al.

    Aims: Arrhythmia-induced cardiomyopathy (AiCM) represents a subtype of acute heart failure (HF) in the context of sustained arrhythmia. Clear definitions and management recommendations for AiCM are lacking. The European Heart Rhythm Association Scientific Initiatives Committee (EHRA SIC) conducted a survey to explore the current definitions and management of patients with AiCM among European and non-European electrophysiologists. Methods and results: A 25-item online questionnaire was developed and distributed among EP specialists on the EHRA SIC website and on social media between 4 September and 5 October 2023. Of the 206 respondents, 16% were female and 61% were between 30 and 49 years old. Most of the respondents were EP specialists (81%) working at university hospitals (47%). While most participants (67%) agreed that AiCM should be defined as a left ventricular ejection fraction (LVEF) impairment after new onset of an arrhythmia, only 35% identified a specific LVEF drop to diagnose AiCM with a wide range of values (5–20% LVEF drop). Most respondents considered all available therapies: catheter ablation (93%), electrical cardioversion (83%), antiarrhythmic drugs (76%), and adjuvant HF treatment (76%). A total of 83% of respondents indicated that adjuvant HF treatment should be started at first HF diagnosis prior to antiarrhythmic treatment, and 84% agreed it should be stopped within six months after LVEF normalization. Responses for the optimal time point for the first LVEF reassessment during follow-up varied markedly (1 day–6 months after antiarrhythmic treatment). Conclusion: This EHRA Survey reveals varying practices regarding AiCM among physicians, highlighting a lack of consensus and heterogenous care of these patients.